FDA Determines Regulatory Review Period for Regranex and Becaplermin Concentrate

Summary

The Food and Drug Administration has officially confirmed the regulatory review period for Regranex and Becaplermin Concentrate, a decision made in response to a patent extension application submitted to the U.S. Patent and Trademark Office.